Large untapped market potential for enhanced nasal drug delivery technology

nWhereas 2% of drugs are currently administered through the mucosal tissues of the nasal cavity, resulting in a total of 43.8MM total prescriptions and $3.4Bn in retail/non-retail sales are via the nasal cavity, only 4.6MM prescriptions are for non-nasal/allergy products, with a market value in 2005 of around $500MM. The market for a rapid-onset, breakthrough pain product administered safely via the nasal mucosa will exceed $2.5Bn by 2015.

Late stage pre-clinical development program 

nNovel LiPoint-based technology is already proven safe and effective for dermal drug delivery. Estimated $2.5MM of investment in technology to date means LiPoint Inc. will be close to IND filing within 1 year post-formation. It is anticipated that subtle proprietary alterations in formulation using the same basic ingredients will lead to multiple product opportunities with the goal of one IND per year for the next 5 years.

Proprietary technology

nProprietary nature of technology in complex IP niche confirmed with multiple independent patent opinions

nOver 5 years of formulation development has been incorporated in LiPoint product concepts

Development strategy to maximize return on investment

nPartners will be sought for the development past proof-of-concept, sales and marketing of LiPoint products

Pipeline includes multiple product opportunities with  different regulatory strategies

nDevelopment strategy includes OTC, 505(b)2 and NDA development of various products in multiple categories and indications

Highly focused, efficient drug development infrastructure

nLimited capital consumption to date; staged investment planned to maximize value and limit dilution

nLean corporate infrastructure enables flexibility to focus development efforts on projects with promising short-term opportunities for commercial development

nHighly beneficial relationship with the KarolinskaResearchCenterand The Royal School of Technology in StockholmSweden (Institute of Surface Chemistry) for discovery and development research, along with use of facilities minimizes research costs. Company owns fully equipped facility for production of research batches of product for animal testing.

nAffiliation with team at SUNY Stony Brook with state-of-the-art screening technology for nasal and mucosal drug delivery systems

nManufacturing of clinical supplies will be outsourced to one of several qualified facilities

Highly qualified and experienced management team

nCEO, Robert Ashley, has over 24 years experience in a variety of operational and management roles in both large and small pharmaceutical companies

nLiPoint inventor, Thomas Sköld, responsible for development of novel drug delivery technology resulting in multiple products and worldwide licensing agreements